Rodriguez SH, et al. - Researchers at the institution of authors assessed neurodevelopmental outcomes among infants treated for retinopathy of prematurity (ROP). Before-and-after retrospective chart reviews, 40 laser-treated infants and 46 primary intravitreal bevacizumab (IVB) treated were identified. Death, hearing loss, bilateral visual impairment (BVI), and cerebral palsy (CP) were primary outcomes. Overall, the primary outcome measures by treatment group did not present any significant differences. However, adjusted BVI odds with laser compared to IVB were significantly higher. Even though IVB was not associated with CP, CP was strongly correlated with both hydrocephalus and BVI. Overall, the authors concluded that visual results are a key element of neurodevelopment. In this analysis, IVB has not been associated with severe developmental disabilities and can protect against vision loss.